Marksans Pharma Share Price Target for 2023, 2025, 2027, 2030, 2035, 2040, and 2050 is based on the company’s growth prospects:— Marksans Pharma Limited is a pharmaceutical company engaged in the manufacture and sale of generic drugs. The company’s share price is subject to various market and industry-related factors, including regulatory changes, competition, and economic conditions.
As an investor or a beginner interested in Marksans Pharma, it is essential to understand the potential of a Marksans Pharma Share Price Target. In this blog post, we will take a closer look at Marksans Pharma share price target with a comprehensive overview of the company’s stock price.
So, whether you are a long-time shareholder or are considering investing in Marksans Pharma for the first time, we will also provide an analysis of Marksans Pharma performance and the outlook for its future growth.
The stock market can be unpredictable, and prices can change rapidly in response to various factors such as economic conditions, global events, or company-specific news. So, we’ll be providing you with Today’s Marksans Pharma Share Price, including changes in value and other relevant information.
Marksans Pharma Overview
Marksans Pharma Limited is a global pharmaceutical company headquartered in Mumbai, India. The company was founded in 1986 and has grown to become one of the leading players in the pharmaceutical industry in India and internationally.
Marksans Pharma specializes in the development, manufacturing, and marketing of generic and branded pharmaceutical products. The company’s product portfolio includes a wide range of therapeutic areas such as cardiovascular, anti-diabetic, anti-infective, pain management, and central nervous system disorders.
The company has a strong presence in the United States, Europe, Australia, and Africa, with sales in over 50 countries worldwide. Marksans Pharma operates a number of manufacturing facilities in India, including a state-of-the-art research and development center in Mumbai.
Marksans Pharma is committed to providing high-quality, affordable healthcare products to patients around the world. The company has a strong focus on research and development and invests heavily in developing new and innovative products to meet the needs of its customers.
In addition, Marksans Pharma has implemented a number of sustainability initiatives to reduce its environmental footprint and minimize the impact of its operations on the environment. The company has also undertaken various social welfare activities to support the communities in which it operates.
Overall, Marksans Pharma is a leading player in the pharmaceutical industry with a strong focus on research and development, a commitment to providing high-quality, affordable healthcare products, and a dedication to sustainability and social responsibility.
Fundamentals of Marksans Pharma
One way to check the Marksans Pharma share price forecast is to look at the research reports and analysis provided by financial institutions and brokerage firms. These firms often provide detailed reports on the company’s financials and future outlook, along with recommendations and target prices.
| DATE | AUTHOR | TARGET |
|---|---|---|
| 16 Mar 2023 | HDFC Securities | 83.06 |
| 21 OCT 2022 | Ventura | 104.00 |
| 06 JUN 2022 | Arihant Capital | 80.00 |
| 14 OCT 2021 | Arihant Capital | 87.00 |
| 11 JUN 2018 | Centrum Broking | 31.00 |
| 11 JUN 2018 | Centrum Broking | 31.00 |
| 19 FEB 2018 | Centrum Broking | 55.00 |
| 27 NOV 2017 | Centrum Broking | 45.00 |
| 30 SEP 2016 | Dynamic Levels | 70.00 |
| 30 JUN 2015 | Karvy | 77.00 |
| 01 JUN 2015 | Karvy | |
| 14 APR 2015 | ICICI Securities Limited | |
| 13 FEB 2015 | Karvy | 77.00 |
| 07 FEB 2015 | Karvy | |
| 21 JAN 2015 | Karvy | 73.00 |
As an investor, you may be wondering what the future holds for Marksans Pharma and its share price. we’ll take a look at the current state of Marksans Pharma and try to predict what its share price might look like in the next 10 to 30 years.
| Years | 1st Target | 2nd Target |
|---|---|---|
| 2023 | ₹85 | ₹100 |
| 2024 | ₹110 | ₹125 |
| 2025 | ₹140 | ₹160 |
| 2026 | ₹170 | ₹190 |
| 2027 | ₹200 | ₹225 |
| 2030 | ₹300 | ₹350 |
| 2040 | ₹600 | ₹700 |
| 2050 | ₹1000 | ₹1200 |
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 85 and a maximum target of INR 100 by the end of 2023. This is based on the company’s strong financial performance in recent years and the expected growth in the pharmaceutical industry.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 110 and a maximum target of INR 125 by the end of 2024. This is based on the company’s expansion plans and the growing demand for pharmaceutical products.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 140 and a maximum target of INR 160 by the end of 2025. This is based on the company’s focus on innovation and research and development.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 170 and a maximum target of INR 190 by the end of 2026. This is based on the company’s plans to expand its product portfolio and increase its market share.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 200 and a maximum target of INR 225 by the end of 2027. This is based on the company’s expected growth in revenue and profits.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 300 and a maximum target of INR 350 by the end of 2030. This is based on the company’s plans to expand globally and increase its presence in emerging markets.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 600 and a maximum target of INR 700 by the end of 2040. This is based on the company’s expected growth in revenue and profits over the long term.
The share price of Marksans Pharma Limited is expected to reach a minimum target of INR 1000 and a maximum target of INR 1200 by the end of 2050. This is based on the company’s continued focus on innovation, research and development, and expansion plans over the long term.
Business Model
The business model of Marksans Pharma revolves around the development, manufacturing, and marketing of pharmaceutical products, both generic and branded, for domestic and international markets. The company has a strong presence in various therapeutic areas and aims to provide high-quality, affordable healthcare products to patients around the world.
The revenue streams of Marksans Pharma include the sale of finished pharmaceutical products, active pharmaceutical ingredients (APIs), and contract manufacturing services. The company also earns revenue from licensing and partnering agreements with other pharmaceutical companies.
Marksans Pharma has a strong focus on research and development and invests heavily in developing new and innovative products to meet the needs of its customers. The company also engages in strategic partnerships and collaborations with other pharmaceutical companies to expand its product portfolio.
The company’s manufacturing facilities are located in India and are equipped with advanced technology and machinery. This allows Marksans Pharma to produce high-quality products at competitive prices.
Marksans Pharma has a global presence, with sales in over 50 countries worldwide. The company has a strong distribution network that includes direct sales, distributors, and partners in various countries.
In addition, Marksans Pharma is committed to sustainability and social responsibility. The company has implemented various initiatives to reduce its environmental footprint and has also undertaken various social welfare activities to support the communities in which it operates.
Overall, Marksans Pharma’s business model is centered around the development, manufacturing, and marketing of high-quality, affordable healthcare products, with a strong focus on research and development, strategic partnerships and collaborations, and a commitment to sustainability and social responsibility.
Competition
| Name | Market Cap. | Total Assets |
| Sun Pharma | 232,111.66 | 29,456.66 |
| Divis Labs | 74,373.68 | 11,691.35 |
| Dr Reddys Labs | 73,001.21 | 20,507.30 |
| Cipla | 71,307.13 | 22,513.55 |
| Torrent Pharma | 52,514.89 | 9,688.83 |
| Zydus Life | 48,550.37 | 15,903.10 |
| Abbott India | 43,994.55 | 2,819.79 |
| Alkem Lab | 37,723.36 | 10,989.18 |
| Lupin | 30,309.20 | 18,940.66 |
| Aurobindo Pharm | 27,729.54 | 18,935.96 |
| GlaxoSmithKline | 21,344.31 | 2,677.61 |
| Gland | 20,055.15 | 7,162.16 |
| Ipca Labs | 19,821.91 | 6,284.35 |
| Pfizer | 16,473.30 | 2,866.91 |
| Laurus Labs | 16,469.25 | 5,007.87 |
| Ajanta Pharma | 15,330.82 | 3,169.18 |
| JB Chemicals | 15,175.29 | 2,129.98 |
| Sanofi India | 13,237.43 | 1,275.80 |
| Glenmark | 12,205.18 | 20,408.95 |
| Suven Pharma | 12,051.11 | 1,616.28 |
| Natco Pharma | 9,564.17 | 4,580.90 |
| Alembic Pharma | 9,563.78 | 5,920.33 |
| Piramal Pharma | 8,221.96 | 6,168.87 |
| AstraZeneca | 8,167.88 | 511.39 |
| Procter&Gamble | 8,053.36 | 616.49 |
| Eris Life | 7,966.43 | 1,918.56 |
| Granules India | 6,851.02 | 3,577.87 |
| Glenmark Life | 4,738.13 | 2,054.31 |
| Caplin Labs | 4,658.91 | 930.65 |
| Jubilant Pharmo | 4,425.63 | 1,780.82 |
| FDC | 4,146.09 | 1,948.92 |
| Hikal | 3,837.74 | 1,742.45 |
| Marksans Pharma | 3,036.20 | 789.68 |
| Aarti Drugs | 2,987.74 | 1,487.04 |
| Indoco Remedies | 2,952.04 | 1,148.52 |
— We’ll take a look at the current state of Marksans Pharma and try to predict what its share price might look like in 2023, 2025, 2027, 2030, 2035, 2040, and 2050 based on the company’s growth prospects.
— We will also provide an analysis of Marksans Pharma performance and the outlook for its future growth.
— Check the Marksans Pharma share price forecast to look at the research reports and analysis provided by Motilal Oswal.
That these share price targets for “Marksans Pharma” are only provided for informational purposes only. It does not constitute a recommendation to buy, sell or hold Marksans Pharma stock. Investors should conduct their own research and analysis and consult with financial experts before making any investment decisions.
